MTAP and gastric cancer: MTAP-ANRIL fusion has been reported in melanoma [112] and CLDN18-ARHGAP26 in gastric cancer, the latter promoting loss of the epithelial phenotype in gastric cancer [113].TMPRSS2 fusions may be defining markers for prostate cancer.